• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
173083 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
* Y5 Z; j: d6 I4 P/ v& J; ^; p: n- X" I
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  $ J) w& S: y5 O1 j2 Y8 |

) \& J/ A: `- |" j: ~, j3 {  u" y, X) ?+ k/ _) a1 c
Sub-category:
, K* C  T% Q5 \0 BMolecular Targets
4 _* {1 X; s! |
0 `+ t$ p# s$ z+ P; a# |. a2 N9 Z2 |3 _7 K
Category:4 u8 {% R/ v4 R0 x" ?
Tumor Biology : M& y  q, a& d1 |

  X& x3 B+ v- {* X# y
& G6 l0 u# d$ J& q$ v& b( q+ dMeeting:
5 Y! p6 @9 q+ w7 d* I2011 ASCO Annual Meeting * I9 o. K3 z- Z4 Y

5 B0 R  }; V: v; h7 c: y0 x3 F8 p) a
Session Type and Session Title:
% A( C) i, Y0 q$ d! @Poster Discussion Session, Tumor Biology
& c9 z4 e( X3 D) l8 I! M7 T! D+ }5 @* v! _8 C  {- t

1 d) a6 {, [4 t& ?3 KAbstract No:
" F# H. r) _: C( Y10517 6 }% R' d* l* _, j1 z2 A. S
( K+ V2 T3 v& j, q3 S

. R& g7 Q- A. i1 S0 Q/ RCitation:
. d7 l. }6 j! G, N6 OJ Clin Oncol 29: 2011 (suppl; abstr 10517)
' h2 C8 r+ z, v% N  I6 }5 S( F) {- j- p6 B' g7 {; q( M
3 i! i$ d. U1 [
Author(s):) m# T1 B- S, z5 Z
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
! i4 L" w2 ^; X5 q; y2 n" O% g/ \2 o) {& x/ ~1 d

/ x1 M1 V' Y1 ^# y' F& t1 y+ \) j
; X8 H8 \8 B8 ^6 @' Z2 H( JAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
, b4 r% R% V; ]" Q$ C  T
" ^8 {8 l; z8 MAbstract Disclosures5 L8 d- p% s4 ]1 y2 j4 |7 z

. V( v' {+ ?1 K7 i& a- i. dAbstract:  p7 \- L. v. W/ g

  n! x* s1 Y5 h* Z9 l# Q8 U! r
! R& _  _4 {+ p3 Y8 q) I% eBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
2 l" }5 c( K) x" h& r6 K1 k% o% [- Z; C

/ H6 _) ]# X8 u3 h# F' M3 B+ W
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 $ Y8 ^% s, ~) l% x0 \2 N
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

  K1 V! `2 d6 W1 a  q! b3 E  N化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
; H6 g/ Z  f( I/ n易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。5 J1 t) k9 x" w) x( I! ^# ]; a
ALK一个指标医院要900多 ...

- ~6 v: _; H  ~7 j  u# I平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?3 q; w' ~: w4 z& `* j" v3 j& q3 V
& b/ w; |! ~. p0 V9 q# ?! k4 `3 t% O
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表